CBSET Inc. is a state-of-the-art preclinical translational research institute dedicated to the advancement of early-stage biomedical technologies. CBSET’s mission is to help our sponsors develop unique tools and novel methods to promote early diagnosis and develop innovative treatments for complex diseases. CBSET specializes in the development and application of novel minimally invasive techniques in the fields of cardiology, endoscopy, surgery, drug and device delivery, drug and device safety, and diagnostic imaging.
View Top Employees from CBSETWebsite | https://cbset.com |
Revenue | $25 million |
Funding | $2.2 million |
Employees | 99 (93 on RocketReach) |
Founded | 2006 |
Address | 500 Shire Way, Lexington, Massachusetts 02421, US |
Phone | (781) 541-5555 |
Fax | (781) 541-5655 |
Technologies |
JavaScript,
HTML,
PHP
+20 more
(view full list)
|
Industry | Research Services, Business Services General, Non Profit, Preclinical contract research organization (CRO), Business Services, Biomedical research, diagnostic imaging, Medical device testing, drug delivery and safety, Interventional cardiology, cardiovascular surgery |
Web Rank | 9 Million |
Keywords | Glp Tumorogenicity Assessment, Biotech Companies In Massachusetts, Cbset, Mechanical Testing Of Biomaterials, Compressive Strength Testing Machine For Biomaterial |
Competitors | Gladstone Institutes, Ontario Institute for Cancer Research, PharmaLegacy Laboratories, The Forsyth Institute, Translational Research Institute Australia |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular CBSET employee's phone or email?
The CBSET annual revenue was $25 million in 2024.
Rami Tzafriri is the Director of Research and Innovation of CBSET.
93 people are employed at CBSET.
CBSET is based in Lexington, Massachusetts.
The NAICS codes for CBSET are [541, 54, 5417, 541714, 54171].
The SIC codes for CBSET are [87, 873].